Serge Messerlian is the President of Actelion Pharmaceuticals US, Inc. where he is focused on building a culture that fosters the company’s commitment to both scientific and commercial excellence and a determination to help patients with rare diseases thrive. He has a track record of success in complex, highly competitive US and ex-US markets, and experience that includes rare diseases, immunology, hematology and oncology. He brings to the role a deep personal connection to rare disease having experienced first-hand the impact these conditions can have on a family. Prior to Actelion US, Inc., Serge led REMICADE and the payer & channel portfolio growth strategies for Janssen Pharmaceuticals’ Immunology. He joined Janssen in 2016 from Baxalta (formerly Baxter), where he served as Vice President and Global Commercial Head for the Biosimilars franchise. Serge has held positions of increasing responsibility within Baxter International including senior leadership roles in rare disease hematology and rare disease immunology. Serge holds a Bachelor of Science in Physiology and Biotechnology and a Master of Science in Human Genetics, both from McGill University, and an MBA from the University of Toronto, Canada. He is an avid runner and an art history enthusiast.